Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough intends to conduct study

Schering-Plough intends to conduct study

4th December 2008

Schering-Plough has said it intends to conduct a clinical study to test for allergic reactions in subjects who take its anesthesia-reversal drug sugammadex.

Planned for next year, the manufacturer is developing the research of the product – known as Bridion – to address issues previously raised.

The study is set to involve healthy volunteers, who will be repeatedly exposed to the drug, which reverses the affects anesthesia has on patients faster than current treatments.

In July this year, European regulators approved Bridion and the product has since been launched in seven countries across the continent – with Schering-Plough saying it plans additional future releases.

The company acquired the drug through its purchase of Organon Biosciences, a year ago.

Last week, Schering-Plough announced an update on its boceprevir clinical research.

Currently in phase III development, the product is the company’s lead investigational oral hepatitis C protease inhibitor and has been said by the organisation to have the potential to be best in its class to fight the condition.

Based in Kenilworth, US, Schering-Plough employs 55,000 people and reported net sales of $12.7 billion (8.75 billion pounds) in 2007.

The company has business operations in more than 140 countries and its products include Vytorin, Remicade and Nasonex.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.